Advertisement
Screener

Perrigo Company plc (PRGO) Material Contracts

Perrigo Company plc Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-08-05: Form 10-Q; Exhibit 10.6; Description Form of Restricted Stock Unit Award Agreement (Performance Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan..
  • 2026-08-05: Form 10-Q; Exhibit 10.5; Description Form of Restricted Stock Unit Award Agreement (Service Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan..
  • 2026-08-05: Form 10-Q; Exhibit 10.3; Description Perrigo Company plc Executive Committee Severance Policy, as amended and restated Effective June 29, 2026 (the “Executive Severance Policy”)..
  • 2026-07-06: Form 8-K/A; Exhibit 10.1; Description Employment Agreement, effective July 3, 2026, by and between Perrigo Pharma International D.A.C. and Albert Manzone..
FiledFormExhibitDescription
2026-08-0510-Q10.6Form of Restricted Stock Unit Award Agreement (Performance Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan.
2026-08-0510-Q10.5Form of Restricted Stock Unit Award Agreement (Service Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan.
2026-08-0510-Q10.3Perrigo Company plc Executive Committee Severance Policy, as amended and restated Effective June 29, 2026 (the “Executive Severance Policy”).
2026-07-068-K/A10.1Employment Agreement, effective July 3, 2026, by and between Perrigo Pharma International D.A.C. and Albert Manzone.
2026-05-058-K10.1Perrigo Company plc 2026 Long-Term Incentive Plan
2026-03-238-K10.1Amended and Restated Credit Agreement, dated March 20, 2026, among Perrigo Company plc, as parent, Perrigo Investments, LLC, as initial borrower, the other subsidiaries of the Parent named therein, as Designated Borrowers, each of the lenders, issuing banks and swing line lenders identified therein, JPMorgan Chase Bank, N.A. and J.P. MORGAN SE, as administrative agent, and JPMorgan Chase Bank, N.A., as collateral agent.

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38